Thallion resumes SHIGATEC trial 'in time for STEC season'
This article was originally published in Scrip
Executive Summary
Thallion Pharmaceuticals is resuming patient enrolment in its Phase II SHIGATEC trial in time for the beginning of the high season for Shiga toxin-producing Escherichia coli (STEC) infections in South America.